Press release

Press Release: Phase 2 clinical trial of Type 2 diabetes drug for treatment of Parkinson’s shows positive and promising results

3 April 2024 Results from a one-year, phase 2 clinical trial of the Type 2 diabetes drug lixisenatide suggest that the treatment may slow the progression of motor symptoms in Parkinson’s disease. The study is published on 4 April in The New England Journal of…


Press release

Press Release: Phase 2 clinical trial of dapansutrile for Parkinson’s confirmed

23 February 2024 Cure Parkinson’s, in partnership with Van Andel Institute, is delighted to announce funding for a Phase 2 clinical of dapansutrile, an anti-inflammatory drug, to determine whether it can slow the progression of Parkinson’s. The DAPA-PD trial will evaluate the safety and tolerability…


Press release

Press Release: Cure Parkinson’s welcomes Rory Cellan-Jones as new patron

7 February 2024 Cure Parkinson’s is delighted to announce that Rory Cellan-Jones, former technology correspondent for the BBC, writer, ‘Movers & Shakers’ podcaster, technology advisor and owner of one the UK’s most beloved rescue dogs, has joined Cure Parkinson’s as a patron. Rory was diagnosed…


Press release

Cure Parkinson’s Director of Clinical Development, Dr Richard Wyse, named on His Majesty The King’s New Year’s Honours List

2 January 2024 Cure Parkinson’s Director of Clinical Development, Dr Richard Wyse, has been selected for His Majesty The King’s New Year’s Honours List, for services to medicine in Parkinson’s disease. Dr Wyse has built an innovative, game-changing programme of research for Parkinson’s; he has…


Press release

2023 Tom Isaacs Award honours Dr Natasha Fothergill-Misbah 

29 September 2023 Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce Dr Natasha Fothergill-Misbah, Research Associate at Newcastle University, as the winner of the 2023 Tom Isaacs Award. The award was presented on September 28 in Newcastle, as part of the annual…